Skip to Content

RhoGAM Ultra-Filtered PLUS Dosage

Generic name: HUMAN RHO(D) IMMUNE GLOBULIN 300ug
Dosage form: injection, solution

Medically reviewed by Drugs.com. Last updated on Aug 29, 2019.

For intramuscular use only.

Dose

Pregnancy and other obstetrical conditions

Dose Indication Notes*
*
: After delivery, obstetric complications, and/or invasive procedures, the volume of the fetal-maternal hemorrhage must be determined to calculate the exact dose of RhoGAM required.
RhoGAM
(300 µg)
(1500 IU)
Postpartum (if the newborn is Rh-positive)
Administer within 72 hours of delivery.
Additional doses of RhoGAM are indicated when the patient has been exposed to > 15 mL of Rh-positive red blood cells. This may be determined by use of qualitative or quantitative tests for fetal-maternal hemorrhage.
Antepartum:
  • Prophylaxis at 26 to 28 weeks gestation
    Administer within 72 hours of suspected or proven exposure to Rh-positive red blood cells resulting from:
  • Amniocentesis, chorionic villus sampling (CVS) and percutaneous umbilical blood sampling (PUBS)
  • Abdominal trauma or obstetrical manipulation
  • Ectopic pregnancy
  • Threatened pregnancy loss after 12 weeks gestation with continuation of pregnancy
  • Pregnancy termination (spontaneous or induced) beyond 12 weeks gestation
If antepartum prophylaxis is indicated, it is essential that the mother receive a postpartum dose if the infant is Rh-positive.
If RhoGAM is administered early in pregnancy (before 26 to 28 weeks), there is an obligation to maintain a level of passively acquired anti-D by administration of RhoGAM at 12-week intervals.
MICRhoGAM
(50 µg)
(250 IU)
Actual or threatened termination of pregnancy (spontaneous or induced) up to and including 12 weeks gestation
Administer within 72 hours
RhoGAM may be administered if MICRhoGAM is not available.
  • Administer RhoGAM every 12 weeks starting from first injection to maintain a level of passively acquired anti-D.
  • If delivery occurs within three weeks after the last antepartum dose, the postpartum dose may be withheld, but a test for fetal-maternal hemorrhage should be performed to determine if exposure to > 15 mL of red blood cells has occurred.
  • If delivery of the baby does not occur 12 weeks after the administration of the standard antepartum dose (at 26 to 28 weeks), a second dose is recommended to maximize protection antepartum.

RhoGAM dosage

Each single dose prefilled syringe of RhoGAM contains 300 µg (1500 IU) of Rho(D) Immune Globulin (Human). This is the dose for the indications associated with pregnancy at or beyond 13 weeks unless there is clinical or laboratory evidence of a fetal-maternal hemorrhage (FMH) in excess of 15 mL of Rh-positive red blood cells.

MICRhoGAM dosage

Each single dose prefilled syringe of MICRhoGAM contains 50 µg (250 IU) of Rho(D) Immune Globulin (Human). This dose will suppress the immune response to up to 2.5 mL of Rh-positive red blood cells. MICRhoGAM is indicated within 72 hours after termination of pregnancy up to and including 12 weeks gestation. At or beyond 13 weeks gestation, RhoGAM should be administered instead of MICRhoGAM.

Multiple Dosage

Multiple doses of RhoGAM are required if a FMH exceeds 15 mL, an event that is possible but unlikely prior to the third trimester of pregnancy and is most likely at delivery. Patients known or suspected to be at increased risk of FMH should be tested for FMH by qualitative or quantitative methods.3 In efficacy studies, RhoGAM was shown to suppress Rh immunization in all subjects when given at a dose of > 20 µg per mL of Rh-positive red blood cells. Thus, a single dose of RhoGAM will suppress the immune response after exposure to < 15 mL of Rh-positive red blood cells. However, in clinical practice, laboratory methods used to determine the amount of exposure (volume of transfusion or FMH) to Rh-positive red blood cells are imprecise. Therefore, administration of more than 20 µg of RhoGAM per mL of Rh-positive red blood cells should be considered whenever a large FMH or red blood cell exposure is suspected or documented. Multiple doses may be administered at the same time or at spaced intervals, as long as the total dose is administered within three days of exposure.1

Transfusion of Rh-incompatible blood or blood products

Administer within 72 hours of suspected or proven exposure to Rh-positive red blood cells.

Dose Indication Notes
MICRhoGAM
(50 µg)
(250 IU)
< 2.5 mL Rh-positive red blood cells RhoGAM may be administered if MICRhoGAM is not available.
RhoGAM
(300 µg)
(1500 IU)
2.5 - 15.0 mL Rh-positive red blood cells
RhoGAM
(300 µg)
(1500 IU)
(multiple syringes)
> 15.0 mL Rh-positive red blood cells Additional doses of RhoGAM are indicated when the patient has been exposed to > 15 mL of Rh-positive red blood cells.
Administer 20 µg of RhoGAM per mL of Rh-positive red blood cell exposure, rounding up to the next whole syringe.
Multiple doses may be administered at the same time or at spaced intervals, as long as the total dose is administered within three days of exposure.

Administration

  • Visually inspect RhoGAM and MicRhoGAM for particulate matter, discoloration and syringe damage prior to administration.
  • Do not use if particulate matter is observed.
  • RhoGAM and MicRhoGAM are clear or slightly opalescent. Do not use if discolored.
  • Administer injection per standard protocol.
Note: When administering RhoGAM intramuscularly, place fingers in contact with glass syringe barrel through windows in shield to prevent possible premature activation of safety guard. Figure
Figure After injection, to engage the safety guard, use free hand to slide safety guard over needle. An audible "click" indicates proper activation. Keep hands behind needle at all times. Dispose of the syringe in accordance with local regulations.

As with all blood products, patients should be observed for at least 20 minutes following administration of RhoGAM or MICRhoGAM.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide